ArticleInvestigational new drugs2026
Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.
Article in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.Nature reviews. Clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a rare and aggressive biliary tract cancer with a poor prognosis. Despite recent advancements in molecularly targeted therapies for patients with IDH1 mutations and FGFR2 fusions, the efficacy of integrating these agents with first-line chemotherapy has not been established. This multicenter, Phase Ib dose de-escalation study, conducted prior to the establishment of chemoimmunotherapy as the standard first-line therapy, evaluated the safety and preliminary efficacy of combining ivosidenib or pemigatinib with gemcitabine and cisplatin in patients with advanced CCA. Eligible patients with no disease progression after three cycles of standard chemotherapy were assigned to receive either ivosidenib or pemigatinib based on their mutation status and chemotherapy. The primary endpoints were to evaluate safety, tolerability, the maximum tolerated dose, and the recommended Phase II dose. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and best response profile. The study opened in January 2020 and closed early in November 2022, enrolling eight patients - seven in the ivosidenib arm (Arm A) and one in the pemigatinib arm (Arm B). Enrollment in Arm B was constrained due to challenges in identifying FGFR2 fusion/rearrangement-positive patients in the first-line setting. Treatment-related toxicities of grade 3 or higher occurred in four patients (66.7%) in Arm A. Regarding efficacy, one patient (16.7%) in Arm A achieved a partial response, while the remaining five had stable disease, with a median progression-free survival (PFS) of 15.4 months in Arm A and a median overall survival (OS) of 22.9 months. Given the selection bias and small sample size, these efficacy analyses must be interpreted with caution. Adding ivosidenib to gemcitabine and cisplatin in this study demonstrated a challenging safety profile in advanced CCA. Further research and dose optimization are warranted to confirm these findings and optimize the integration of targeted therapies into first-line regimens.
Indexed as
Identifiers
41678089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.